Despite advances in early-stage lung cancer treatment, a significant number of patients experience disease recurrence after surgery or initial therapy. A novel study has now demonstrated that a blood test (liquid biopsy) can reliably detect lingering lung cancer traces even in the earliest clinical stages, long before a tumor is large enough to show up on a scan. This real-time genetic monitoring detailed in an article appearing in The Journal of Molecular Diagnostics, published by Elsevier, accurately predicts relapse risk, opening a critical window for timely, personalized therapeutic interventions.

A new study reveals that people are willing to sacrifice thousands of dollars to protect their privacy. By analyzing a legal reform that allowed personal injury plaintiffs to remain anonymous in court, the researchers found that insurance settlements increased by 12–17% once the risk of public exposure of sensitive health and financial information was removed. The findings provide rare real-world evidence that privacy has substantial economic value.